LYEL
Lyell Immunopharma
Get Prediction
Get AI stock predictions on your device
About This Company
Lyell Immunopharma specializes in cell therapy, focusing on the reprogramming of T-lymphocytes for the treatment of solid tumors. The company’s technologies are applicable regardless of biological targets and their associated pathways, and are utilized in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy. Lyell Immunopharma is currently developing a pipeline of products designed to deliver comprehensive therapeutic effects across various forms of solid tumors that are difficult to treat.
Get AI Stock Predictions Now
Download our app for real-time AI-powered stock predictions on iOS, Android, Windows and macOS
